GENE ONLINE|News &
Opinion
Blog

2025-12-01|

Study Identifies Tenascin-C Positive Fibroblasts as Key Players in Basal Cell Carcinoma Progression

by GOAI
Share To

A recent study conducted by researchers, including Luo et al., has identified a notable subset of cancer-associated fibroblasts (CAFs) in basal cell carcinoma (BCC). The study, which will appear in the *Journal of Translational Medicine*, highlights fibroblasts positive for tenascin-C (TNC) as playing a significant role in the tumor microenvironment. Using advanced single-cell and spatial transcriptomics techniques, the research provides new insights into the cellular dynamics within BCC.

The findings reveal that TNC-positive CAFs are closely associated with the progression of BCC. By employing state-of-the-art methodologies, the team was able to map out these cells’ spatial distribution and gene expression profiles within tumor tissues. This approach allowed for a detailed understanding of how TNC-positive CAFs interact with other components of the tumor microenvironment. The study represents an important step forward in uncovering cellular mechanisms underlying BCC development and progression.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
LATEST
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
2025-12-04
2025 Healthcare+ Expo Taiwan
Taipei, Taiwan
Scroll to Top